FEMME-TAB 20/100 levonorgestrel 100mcg ethinylestradiol 20mcg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

femme-tab 20/100 levonorgestrel 100mcg ethinylestradiol 20mcg film-coated tablet blister pack

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 100 microgram; ethinylestradiol, quantity: 20 microgram - tablet, film coated - excipient ingredients: gelatin; macrogol 4000; magnesium stearate; maize starch; lactose monohydrate; titanium dioxide; hypromellose - oral contraception

FEMME-TAB 30/150 levonorgestrel 150mcg ethinylestradiol 30mcg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

femme-tab 30/150 levonorgestrel 150mcg ethinylestradiol 30mcg film-coated tablet blister pack

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: gelatin; hypromellose; iron oxide yellow; titanium dioxide; magnesium stearate; lactose monohydrate; maize starch; macrogol 4000 - oral contraception

JORVEZA budesonide 1 mg orally disintegrating tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

jorveza budesonide 1 mg orally disintegrating tablet blister pack

dr falk pharma australia pty ltd - budesonide, quantity: 1 mg - tablet, orally disintegrating - excipient ingredients: magnesium stearate; mannitol; macrogol 6000; sodium acid citrate; sodium dihydrogen citrate; sodium bicarbonate; sucralose; povidone; docusate sodium - jorveza is indicated for the treatment of eosinophilic esophagitis (eoe) in adults

JORVEZA budesonide 0.5 mg orally disintegrating tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

jorveza budesonide 0.5 mg orally disintegrating tablet blister pack

dr falk pharma australia pty ltd - budesonide, quantity: 0.5 mg - tablet, orally disintegrating - excipient ingredients: magnesium stearate; mannitol; macrogol 6000; sodium acid citrate; sodium dihydrogen citrate; sodium bicarbonate; sucralose; povidone; docusate sodium - jorveza? is indicated for the treatment of eosinophilic oesophagitis (eoe) in adults.

FEMME-TAB ED 30/150 150mcg ethinylestradiol 30mcg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

femme-tab ed 30/150 150mcg ethinylestradiol 30mcg film-coated tablet blister pack

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: titanium dioxide; iron oxide red; gelatin; maize starch; macrogol 4000; magnesium stearate; hypromellose; lactose monohydrate - oral contraception

Ramipril TAD 1.25 mg tablets Malta - English - Medicines Authority

ramipril tad 1.25 mg tablets

tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril - tablet - ramipril 1.25 mg - agents acting on the renin-angiotensin system

Ramipril TAD 2.5 mg tablets Malta - English - Medicines Authority

ramipril tad 2.5 mg tablets

tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril - tablet - ramipril 2.5 mg - agents acting on the renin-angiotensin system

Ramipril TAD 5 mg tablets Malta - English - Medicines Authority

ramipril tad 5 mg tablets

tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril - tablet - ramipril 5 mg - agents acting on the renin-angiotensin system

Ramipril TAD 10 mg tablets Malta - English - Medicines Authority

ramipril tad 10 mg tablets

tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril - tablet - ramipril 10 mg - agents acting on the renin-angiotensin system

JAKAVI ruxolitinib (as phosphate) 10 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

jakavi ruxolitinib (as phosphate) 10 mg tablet blister pack

novartis pharmaceuticals australia pty ltd - ruxolitinib phosphate, quantity: 13.2 mg (equivalent: ruxolitinib, qty 10 mg) - tablet - excipient ingredients: hyprolose; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium starch glycollate type a - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis.,jakavi is indicated for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.,jakavi is indicated for the treatment of patients aged 12 years and older with acute graft-versus-host disease who have inadequate response to corticosteroids.,jakavi is indicated for the treatment of patients aged 12 years and older with chronic graft-versus-host disease who have inadequate response to corticosteroids.